Business plan, headache for multinational firms

Reflecting increasing uncertainty due to the government’s pressure to slash drug prices, multinational drug firms in Korea are delaying the formulation of their business plans for next year.

At this time of the year, foreign drug manufactures usually flesh out their sales targets, profit goals, investment scale and other key components of their plans. But now, they say that things are put o...